Related Experiment Videos
[Long-term therapy in chronic hepatitis C with recombinant alpha interferon]
R Siciliano1, B A Trovato, M Romano
1Istituto di Medicina Interna e Geriatria, Università degli Studi di Catania.
Rivista Europea Per Le Scienze Mediche E Farmacologiche = European Review for Medical and Pharmacological Sciences = Revue Europeenne Pour Les Sciences Medicales Et Pharmacologiques
|May 1, 1994
Summary
Long-term alpha-interferon (alpha-IFN) therapy for Chronic Hepatitis C shows effectiveness in achieving remission. This study compared two types of alpha-IFN, finding sustained responses beneficial compared to shorter treatment durations.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- The optimal dosage and duration for Chronic Hepatitis C (CH-C) therapy using alpha-interferon (alpha-IFN) remain subjects of ongoing research.
- Alpha-interferon exhibits significant antiviral activity, making it a key therapeutic agent for CH-C.
- Understanding the long-term efficacy and safety profiles of different alpha-IFN formulations is crucial for patient management.
Purpose of the Study:
- To evaluate the efficacy and safety of long-term alpha-interferon therapy in patients with Chronic Hepatitis C.
- To compare the therapeutic outcomes of recombinant alpha-interferon-2a (r-alpha-IFN-2a) versus recombinant alpha-interferon-2b (r-alpha-IFN-2b).
- To assess the impact of extended treatment duration on sustained virological response.
Main Methods:
- A study involving 35 patients diagnosed with Chronic Hepatitis C.
- Patients were divided into two groups: Group A (21 patients) received r-alpha-IFN-2a, and Group B (14 patients) received r-alpha-IFN-2b.
- Therapy involved a dosage of 3 MU thrice weekly for 12 months, with follow-up assessments ranging from 6 to over 24 months.
Main Results:
- An overall Complete Response (CR) rate of 49.3% was observed, with a Long-Term Complete Response (LTCR) rate of 19.3%.
- Group A showed a higher percentage of Partial Response (PR) compared to Group B, while Group B had a higher percentage of No Response (NR).
- Similar rates of CR and LTCR were noted between the two treatment groups; side effects were observed in a minority of patients.
Conclusions:
- Long-term alpha-interferon therapy for Chronic Hepatitis C is effective in achieving clinical and biochemical remission.
- Extended treatment durations appear to yield a greater number of sustained responses compared to shorter therapy schedules.
- Both r-alpha-IFN-2a and r-alpha-IFN-2b demonstrated comparable efficacy in achieving long-term responses, suggesting potential therapeutic value in prolonged treatment regimens.